For this reason, an opportunity to enhance CAR T cell efficacy is represented by “armored’’ CAR T constructs, expressing homing receptors or chemokine, such as the anti-mesothelin CAR T construct constitutively expressing the cytokine IL-7 and the chemokine CCL19 (Figure 1) to guide the infused product to the tumor site. This evidence concerns the gene MSLN and neoplasm.